1. Scrip
  2. >>Business

Interview: Setting The Course For Takeda’s R&D Future (Part 2)

 
• By Ian Haydock

Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company’s chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 12 months.

In the second and final part of this interview, conducted at Takeda Pharmaceutical Co. Ltd.’s Tokyo headquarters during one of his regular visits to Japan, Dr. Andrew Plump assesses the company’s current pipeline and highlights some of what he sees as the major mid-term assets and their advantages.

For Part 1 see ([A#sc099056])

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Ever The Outlier, Biotech Outpaces Broader Stocks

 
• By Mandy Jackson

Public Company Edition: The US jobs report for August hurt the S&P 500 and Dow Jones, but the XBI rose 2.2% and is up 6% year-to-date. Despite signs of life, with a recent small IPO from Curanex and a larger one proposed by LB Pharmaceuticals, fundraising was down in Q2.

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart

 
• By Joseph Haas

Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

What’s Next For OMass After Roche Licensing Deal

 
• By Manas Mishra

OMass Therapeutics has signed its debut licensing deal with Roche’s Genentech unit. Its CEO Rosamond Deegan talked to Scrip about what drew Roche’s interest to the preclinical IBD program, the company’s lead assets and the potential for other deals.

More from Scrip

Executives On The Move: New CEO At Mitsubishi Tanabe Pharma

Recent moves in the industry include C-suite changes at Mitsubishi Tanabe Pharma and Oculis Holding, plus clock.bio gets a new chief business officer from BioNTech.

Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia

 
• By Mandy Jackson

Approval in alpha- and beta-thalassemia by a Sept. 7 action date seemed assured, but an FDA review of proposed REMS regarding potential liver injury pushed it back to Dec. 7.

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

 
• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.